dc.contributor.author | Cojocaru, E | |
dc.contributor.author | Thway, K | |
dc.contributor.author | Fisher, C | |
dc.contributor.author | Messiou, C | |
dc.contributor.author | Zaidi, S | |
dc.contributor.author | Miah, AB | |
dc.contributor.author | Benson, C | |
dc.contributor.author | Gennatas, S | |
dc.contributor.author | Huang, P | |
dc.contributor.author | Jones, RL | |
dc.date.accessioned | 2021-01-27T15:53:36Z | |
dc.date.issued | 2020-12-01 | |
dc.identifier.citation | Anticancer research, 2020, 40 (12), pp. 7003 - 7007 | |
dc.identifier.issn | 0250-7005 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4320 | |
dc.identifier.eissn | 1791-7530 | |
dc.identifier.doi | 10.21873/anticanres.14725 | |
dc.description.abstract | BACKGROUND/AIM: Clear cell sarcoma (CCS) is an aggressive sarcoma subtype, resistant to conventional anthracycline-based chemotherapy and radiation. The diagnosis is often challenging due to similarities with malignant melanoma. PATIENTS AND METHODS: We aimed to analyse the activity of gemcitabine-based chemotherapy in a cohort of patients with CCS treated at the Royal Marsden Hospital. RESULTS: Five patients with metastatic CCS received gemcitabine as first- or second-line systemic therapy. The median time-to-progression was 10 weeks. The median number of cycles of gemcitabine-based therapy was 3 (range=2-7 cycles). Median overall survival in our cohort was 66 months from the initial diagnosis but in the metastatic setting, the overall survival was reduced to 28 months. CONCLUSION: Gemcitabine-based therapy has modest activity in CCS. There remains a significant unmet medical need for novel, effective therapies for this disease. | |
dc.format | Print | |
dc.format.extent | 7003 - 7007 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | INT INST ANTICANCER RESEARCH | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Sarcoma, Clear Cell | |
dc.subject | Soft Tissue Neoplasms | |
dc.subject | Deoxycytidine | |
dc.subject | Antimetabolites, Antineoplastic | |
dc.subject | Adult | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.title | Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-11-08 | |
rioxxterms.versionofrecord | 10.21873/anticanres.14725 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2020-12 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Anticancer research | |
pubs.issue | 12 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology | |
pubs.publication-status | Published | |
pubs.volume | 40 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Molecular and Systems Oncology | |
dc.contributor.icrauthor | Cojocaru, Elena | |
dc.contributor.icrauthor | Huang, Paul | |